Diclofenac transdermal second generation - Crescita Therapeutics

Drug Profile

Diclofenac transdermal second generation - Crescita Therapeutics

Alternative Names: Diclofenac sodium topical solution 2% w/w; MNK-395; NRI-1004; Pennsaid 2%; Pennsaid Gel; Pennsaid Plus; Pennsaid Viscous Solution

Latest Information Update: 17 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nuvo Research
  • Developer Horizon Pharma; NovaMedica; Nuvo Research
  • Class Antipyretics; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Phenylacetates; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Musculoskeletal pain

Most Recent Events

  • 15 May 2017 Topline efficacy data from a phase III trial in Musculoskeletal pain released by Nuvo Pharmaceuticals
  • 10 May 2017 Nuvo Research completes the phase III (2016 Pennsaid 2% Trial for Musculoskeletal pain in Germany (9216223)
  • 01 May 2017 United States District Court for the District of New Jersey upheld the validity patent claims covering Pennsaid 2% by Horizon Pharma and prevented Actavis from launching a generic version of Pennsaid 2% in the US until October 2027 in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top